A tiny pill steadies immune systems that attack themselves

In Leiden, researchers presented the first clinical results for leniolisib in a wider group of people whose immune systems are mis-wired by rare genetic conditions. All 13 participants who finished the 20-week Phase II study chose to keep taking the drug in a long-term extension, and the treatment shrank enlarged spleens in nearly everyone measured while showing early gains in lung and liver markers.

SDG 3 · Good health and well-being — Mechanism: tech innovation